Howard B. Dickler, MD

Resources:

Elected 1978
The CHI is envisioned as a cooperative enterprise, with representatives form many NIH Institutes working together on focused projects with clear shared goals. The Center will provide specific technologies often unavailable to individual laboratories because of cost, complexity, and novelty, incorporated into three technology centers dedicated to: assays of immune cells and their products, mainly based on flow cytometry and other emerging multiplexed techniques; high-throughput systems technologies, involving the use of new methods for large scale examination of the genome, gene expression epigenetic modulation, as well as the proteome, lipidome, and metabolome, and the application of advanced biostatical and computer modeling methods for mining these diverse data to aid in understanding immune function and pathology; protocol development, with staff dedicated to the efficient translation to the clinic with appropriate ethical and regulatory requirements for human research. The Center's focus is human immunology, normal but especially pathologic, with an emphasis on shared pathophysiologic mechanisms that underlie disease. This includes recognized immunologially-mediated diseases, organ specific autoimmunity, and the role of inflammation in a wide variety of common diseases, including cancer, atherosclerosis, and neurologic degeneration.